Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/10/2020
SIETES contiene 93130 citas

 
 
<< anterior 21 a 40 de 15082 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
22. Cita con resumen
Rome BN, Avorn J. Drug evaluation during the covid-19 pandemic. N Engl J Med 2020;382:11 de junio. [Ref.ID 103661]
23. Cita con resumen
Taylor P. COVID-19 round-up: medicines on trial. PMLiVE 2020:9 de junio. [Ref.ID 103659]
24. Cita con resumen
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:14 de mayo. [Ref.ID 103652]
25. Cita con resumen
Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, Fois E, Lepeule R, Szwebel T-A, Lescure F-X, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotsky J-M, Michel M, Perrodeau E, et al.. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:14 de mayo. [Ref.ID 103651]
26. Cita con resumen
28. Cita con resumen
Wise J. Covid-19 and thrombosis: what do we know about the risks and treatment?. BMJ 2020;369:21 de mayo. [Ref.ID 103635]
29.Tiene citas relacionadas Cita con resumen
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020:22 de mayo. [Ref.ID 103632]
30.Tiene citas relacionadas Cita con resumen
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, et al. for the ACTT-1 Study Group Members. Remdesivir for the treatment of covid-19 — Preliminary report. N Engl J Med 2020:22 de mayo. [Ref.ID 103631]
31.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, et al.. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:29 de abril. [Ref.ID 103630]
32. Cita con resumen
Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd C, Criner GJ, Donaldson GC, Dreher M, Fan VS, Gershon AS, et al.. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline . Am J Respir Crit Care Med 2020;201:1 de mayo. [Ref.ID 103620]
33. Cita con resumen
Lafaurie M, Olivier P, Khouri C, Atzenhoffer M, Bihan K, Durrieu G, Montastruc J-L. Myocardial infarction and ischemic stroke with vasoconstrictors used as nasal decongestant for common cold: a French pharmacovigilance survey. Eur J Clin Pharmacol 2020;76:603-4. [Ref.ID 103616]
36. Cita con resumen
Anónimo. NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. National Institute of Allergy and Infectious Diseases 2020:29 de abril. [Ref.ID 103612]
37. Cita con resumen
Sakoulas G, El Sahly H, Ellison III RT. Chloroquine and hydroxychloroquine: old drugs in a new COVID-19 world. Journal Watch 2020:. [Ref.ID 103608]
38. Cita con resumen
Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, Aizer A, Holmes D, Bernstein S, Spinelli M, Park DS, Chinitz LA, Jankelson L. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med 2020:24 de abril. [Ref.ID 103600]
39. Cita con resumen
Iacobucci G. Sixty seconds on . . . the RECOVERY trial. BMJ 2020;369:20 de abril. [Ref.ID 103597]
40.Enlace a cita original Cita con resumen
Mullard A. Flooded by the torrent: the COVID-19 drug pipeline. Lancet 2020;395:8 de abril. [Ref.ID 103591]
Seleccionar todas
 
<< anterior 21 a 40 de 15082 siguiente >>